Abstract:Recessive dystrophic epidermolysis bullosa (RDEB) is a rare autosomal inherited skin blistering disorder caused by mutations in the type VII collagen gene (COL7A1). Bonafont et. al. reported an electroporation-based COL7A1 exon 80 deletion strategy for RDEB treatment, which efficiently restored functional type VII collagen (C7) in the RDEB patient keratinocyte cells (RDEBK)ex vivo. Following this strategy, we synthesized and tested a library of hyperbranched aminated polyesters (HAPEs) as gene delivery vectors and developed topical non-viral gene editing therapies for RDEB. The CRISPR/Cas9 machinery was delivered by the selected HAPEs in either an all-in-one plasmid or ribonucleoprotein complex (RNP) to cells. HAPE-D/DNA complexes achieved higher or comparable gene expression (96% positive cells), compared to commercial reagents including LipofectamineTM 3000, XfectTM, jetPEI®, and jetOPTIMUS®. Furthermore, CRISPR/Cas9 plasmid delivered by HAPE-D contributed to around 25% targeted deletion of COL7A1 exon 80 and bulk C7 restoration in RDEBK polyclones, while maintaining good cell viability. The best protein delivery HAPE (HAPE-P) demonstrated great ability on universal protein delivery and successfully delivered cytosolic protein such as bovine serum albumin, immunoglobulin, saporin and β-Galactosidase into HeLa and RDEBK cells. The cytosolic delivered β-Galactosidase had 5 times better enzymatic activity than commercial reagents like PULsin® and Pierce™ Protein Transfection Reagent in HeLa and RDEBK cells (P<0.0001). Complexed with HAPE-P, CRISPR Cas9 RNP introduced 69% indels and 32% targeted exon 80 deletion in human embryonic kidney polyclones. In summary, the newly developed HAPEs in this study can efficiently deliver a CRISPR/Cas9 system in either DNA or ribonucleoprotein format. The non-viral gene editing therapy developed here achieved efficient C7 restoration in RDEBK cells, which has a high potential for use as a topical treatment for RDEB and can be adapted to other diseases.

Strategy for the optimization of read-through therapy for junctional epidermolysis bullosa with COL17A1 nonsense mutation

Personalized Development of Antisense Oligonucleotides for Exon Skipping Restores Type XVII Collagen Expression in Junctional Epidermolysis Bullosa

Novel readthrough agent suppresses nonsense mutations and restores functional type VII collagen and laminin 332 in epidermolysis bullosa

Stop codon readthrough as a treatment option for epidermolysis bullosa—Where we are and where we are going

Amlexanox Enhances Premature Termination Codon Read-Through in COL7A1 and Expression of Full Length Type VII Collagen: Potential Therapy for Recessive Dystrophic Epidermolysis Bullosa

CRISPR-Cas9-based Non-Viral Gene Editing Therapy for Topical Treatment of Recessive Dystrophic Epidermolysis Bullosa

Cytosine Deaminase Base Editing to Restore COL7A1 in Dystrophic Epidermolysis Bullosa Human: Murine Skin Model

COL17A1 editing via homology-directed repair in junctional epidermolysis bullosa

Development of Minicircle Vectors Encoding COL7A1 Gene with Human Promoters for Non-Viral Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa.

Highly efficient CRISPR/Cas9‐mediated exon skipping for recessive dystrophic epidermolysis bullosa

Is Exon Skipping a Viable Therapeutic Approach for Vascular Ehlers-Danlos Syndrome with Mutations in COL3A1 Exon 10 or 15?

532 Sirna Based Non-Viral Gene Therapy for the Treatment of Epidermolysis Bullosa Simplex(ebs)

Gene therapy: pursuing restoration of dermal adhesion in recessive dystrophic epidermolysis bullosa.

A Non‐viral Gene Therapy for Treatment of Recessive Dystrophic Epidermolysis Bullosa

200 A Comparison of Minicircle Vectors Expressing COL7A1 under the Control of Human Promoters for the Treatment of Recessive Dystrophic Epidermolysis Bullosa

834 CRISPR/Cas9 Based COL7A1 Genomic Editing in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Via Non-Viral Polymer Delivery System

901 Non-viral Gene Editing Therapy for Recessive Dystrophic Epidermolysis Bullosa: CRISPR/Cas9 Mediated COL7A1 Exon 80 Deletion Strategy

Mechanism-based approach in designing patient-specific combination therapies for nonsense mutation diseases

455 Non-viral Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa: Hyper Branched Aminated Polyesters Mediated Minicircle DNA Delivery

Highly Efficient Ex Vivo Correction of COL7A1 through Ribonucleoprotein-Based CRISPR/Cas9 and Homology-Directed Repair to Treat Recessive Dystrophic Epidermolysis Bullosa

Splice modulation strategy applied to deep intronic variants in COL7A1 causing recessive dystrophic epidermolysis bullosa